

lesions a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof, and a pharmaceutically acceptable carrier or diluent.

15. The method of both inhibiting proliferation of myeloma cells and suppressing bone resorption according to claim 14, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 1 to 20 mg per day.

16. The method of both inhibiting proliferation of myeloma cells and suppressing bone resorption according to claim 14, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 3 to 10 mg per day.

17. The method of both inhibiting proliferation of myeloma cells and suppressing bone resorption according to any one of claims 14-16, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally.

18. A method of inhibiting proliferation of myeloma cells, comprising administering to a patient suffering from multiple myeloma a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof, and a pharmaceutically acceptable carrier or diluent.

19. The method of inhibiting proliferation of myeloma cells according to claim 18, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 1 to 20 mg per day.

C1
Contd

20. The method of inhibiting proliferation of myeloma cells according to claim 18, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is 3 to 10 mg per day.

21. The method of inhibiting proliferation of myeloma cells according to any one of claims 18-20, wherein the pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally.
